Cereal Proteins

Cereals have a protein content of about 10%, which are classified by their solubility according to Thomas Burr Osborne (1919, The vegetable proteins.):

Albumins + globulins:
soluble in saline
Prolamins:
soluble in ethanol
Glutelins:
soluble in propanol/urea/DTE

Prolamins and glutelins like gliadin and glutenin from wheat play a crucial role in celiac disease pathophysiology.

Cereal protein extracts are available for:
  • Barley
  • Spelt
  • Rice
  • Rye
  • Oat
  • Corn
  • Wheat
  • Millet
  • Soy (corresponding protein extracts)
  • Wheat Durum

Pure gliadin peptides, recombinantly produced in E. coli (fused to a carrierprotein), are available for γ-gliadin (26 mer, aa 59-84) as well as α-gliadin (33mer, aa 57-89). For these gliadin-peptides also the deamidated versions are available.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland